PD-L1 Inhibition With MPDL3280A for Solid Tumors

Cancer immunotherapy has become a popular anticancer approach, with the goal of stimulating immune responses against tumor cells. Recent evidence has demonstrated that the use of monoclonal antibodies targeting the programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) checkpoint pathway can result in well-tolerated clinical responses in a wide variety of tumor types. This review summarizes the safety, clinical activity and biomarker data...